EPISODE · Oct 30, 2025 · 16 MIN
NurExone Biologic's Revolutionary Approach to Nerve Regeneration
Send us Fan MailIn this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer, along with the company’s Founder, VP Business Development & Active Chairman, Yoram Drucker to talk about NurExone's novel regenerative exosome-based therapies development pipeline for central nervous system injuries, led by spinal cord and optic nerve injuries, both multi-billion-dollar markets. Our conversation covers key differentiators from other developments targeting those indications, the company's path towards clinical trials, and its financial capabilities and strategy to advance its development programs.
Embed this episode
What this episode covers
Send us Fan Mail In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer, along with the company’s Founder, VP Business Development & Active Chairman, Yoram Drucker to talk about NurExone's novel regenerative exosome-based therapies development pipeline for central nervous system injuries, led by spinal cord and optic nerve injuri...
NOW PLAYING
NurExone Biologic's Revolutionary Approach to Nerve Regeneration
No transcript for this episode yet
Similar Episodes
No similar episodes found.